These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30762807)

  • 21. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis.
    Kamat AM; Lerner SP; O'Donnell M; Georgieva MV; Yang M; Inman BA; Kassouf W; Boorjian SA; Tyson MD; Kulkarni GS; Chang SS; Konety BR; Svatek RS; Balar A; Witjes JA
    Eur Urol Oncol; 2020 Jun; 3(3):318-340. PubMed ID: 32201133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer.
    Tabayoyong WB; Kamat AM; O'Donnell MA; McKiernan JM; Ray-Zack MD; Palou J; Brausi M; Black PC; Williams SB
    Eur Urol Focus; 2018 Jul; 4(4):512-521. PubMed ID: 30190111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.
    Dinnes J; Ferrante di Ruffano L; Takwoingi Y; Cheung ST; Nathan P; Matin RN; Chuchu N; Chan SA; Durack A; Bayliss SE; Gulati A; Patel L; Davenport C; Godfrey K; Subesinghe M; Traill Z; Deeks JJ; Williams HC;
    Cochrane Database Syst Rev; 2019 Jul; 7(7):CD012806. PubMed ID: 31260100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
    Lotan Y; Inman BA; Davis LG; Kassouf W; Messing E; Daneshmand S; Canter D; Marble HT; Joseph AM; Jewell S; Boorjian SA
    J Urol; 2019 Nov; 202(5):920-926. PubMed ID: 31120373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of fluorescence in situ hybridization to predict patient response to intravesical Bacillus Calmette-Guérin therapy for bladder cancer: A diagnostic meta-analysis and systematic review.
    Bao Y; Tu X; Chang T; Qiu S; Yang L; Geng J; Quan L; Wei Q
    Medicine (Baltimore); 2018 Sep; 97(36):e12227. PubMed ID: 30200146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(12):1-123. PubMed ID: 34484486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis.
    Chou R; Gore JL; Buckley D; Fu R; Gustafson K; Griffin JC; Grusing S; Selph S
    Ann Intern Med; 2015 Dec; 163(12):922-31. PubMed ID: 26501851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis.
    Du J; Wang SH; Yang Q; Chen QQ; Yao X
    World J Surg Oncol; 2016 Apr; 14():137. PubMed ID: 27129876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials.
    Chen S; Zhang N; Shao J; Wang X
    Int J Surg; 2018 Apr; 52():248-257. PubMed ID: 29499363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: A systematic review and meta-analysis.
    Kang W; Cui Z; Chen Q; Zhang D; Zhang H; Jin X
    Oncotarget; 2017 Apr; 8(14):23880-23890. PubMed ID: 27823975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
    Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
    Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
    Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
    Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation.
    Gurung PMS; Barnett AR; Wilson JS; Hudson J; Ward DG; Messing EM; Bryan RT
    Eur Urol Focus; 2020 Jul; 6(4):683-697. PubMed ID: 30803927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert
    Cowan B; Klein E; Jansz K; Westenfelder K; Bradford T; Peterson C; Scherr D; Karsh LI; Egerdie B; Witjes A; Trainer A; Harris R; Goldfarb B; Flax S; Kroeger R; Boyd B; Liao J; Patel S; Bridge J; Reuter V; Quigley N; Brown S; Zhao S; Satya M; Bates M; Simon IM; Campbell S; Lotan Y
    BJU Int; 2021 Dec; 128(6):713-721. PubMed ID: 33793062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
    Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
    Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression.
    Chen PC; Yu HJ; Chang YH; Pan CC
    J Clin Pathol; 2013 Feb; 66(2):113-9. PubMed ID: 23087329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer.
    Kipp BR; Tanasescu M; Else TA; Bryant SC; Karnes RJ; Sebo TJ; Halling KC
    J Mol Diagn; 2009 Mar; 11(2):148-54. PubMed ID: 19179455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer.
    Galesloot TE; Grotenhuis AJ; Kolev D; Aben KK; Bryan RT; Catto JWF; Cheng KK; Conroy S; Dyrskjøt L; Fleshner NE; James ND; Lamy P; Lindskrog SV; Malats N; Mengual L; Verhaegh G; Zeegers MP; Kiemeney LALM; Vermeulen SH
    Eur Urol Oncol; 2022 Feb; 5(1):70-83. PubMed ID: 34353775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system.
    Kim HS; Jeong CW; Kwak C; Kim HH; Ku JH
    World J Urol; 2019 Sep; 37(9):1867-1877. PubMed ID: 30535715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.